HIM
SNDX icon

Hillhouse Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Hillhouse Investment Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-203,915
Closed -$1.79M – 54
2017
Q4 		$1.79M Sell
203,915
-27,118
-12% -$268K 0.03% 45
2017
Q3 		$2.7M Sell
231,033
-14,416
-6% -$177K 0.04% 46
2017
Q2 		$3.43M Hold
245,449
– – 0.05% 54
2017
Q1 		$3.37M Buy
+245,449
New +$2.55M 0.07% 47

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hillhouse Investment Management's SNDX Position: Q1 2018 in Review

Hillhouse Investment Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2018, closing a stake of 203,915 shares — an estimated $1.79M sold.

Hillhouse Investment Management first reported a position in SNDX in Q1 2017 and held it in 4 quarters. The position peaked at $3.43M in Q2 2017. 72 funds tracked by Wall St. Rank hold SNDX as of Q1 2018.

  • Hillhouse Investment Management reported no remaining Syndax Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Hillhouse Investment Management sold 203,915 Syndax Pharmaceuticals shares in Q1 2018, an estimated $1.79M.
  • Hillhouse Investment Management first reported a position in Syndax Pharmaceuticals in Q1 2017 and held it in 4 quarters.
  • Hillhouse Investment Management's Syndax Pharmaceuticals position peaked at $3.43M in Q2 2017.
  • 72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2018.

Based on Hillhouse Investment Management's 13F filing for Q1 2018, filed 15 May 2018.